CD103+ T Cells May Be a Useful Biomarker in Borrmann Type 4 Gastric Cancer

Cancer Diagn Progn. 2022 May 3;2(3):384-390. doi: 10.21873/cdp.10121. eCollection 2022 May-Jun.

Abstract

Background/aim: Recently, several studies have reported that CD103 + T cells are associated with antitumor immunity in gastric cancer (GC). However, the significance of CD103 + T cells in Borrmann type 4 GC remains unclear. The aim of this study is to assess the association of CD103 + T cells with type 4 GC.

Materials and methods: Tissue samples obtained from surgically resected specimens of patients with type 4 GC were collected, and immunohistochemical staining was performed to detect the presence of CD103 + T cells.

Results: A total of 46 patients were analyzed. In some patients, high CD103 expression was observed, and patients with high CD103 expression tended to have a better prognosis than those with low CD103 expression. In particular, for patients who receive doublet chemotherapy after surgery, high CD103 expression was associated with a good prognosis.

Conclusion: CD103 + T cells may be a prognostic marker in type 4 GC.

Keywords: CD103; Gastric cancer; diffuse type; type 4.